The SECURE-IBD registry of 1439 cases of COVID-19 in IBD patients from 47 countries has demonstrated that thiopurine therapy (aOR 4.08, 95% CI 1.73–9.61) and combination therapy with anti-TNF and thiopurine (aOR 4.01, 95% CI 1.65–9.78) were associated with increased risks of severe COVID-19 outcomes.6 This registry is ongoing and continuing to collect important information on outcomes of COVID-19 specific to IBD. Here, TNF is linked to inflammatory bowel disease.